Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Praxis Precision Medicines, Inc. (PRAX)

Praxis Q3 2026 net loss widens to $94.2 million; cash totals $1.3 billion

Mixed Impact 3 of 5 earnings

Praxis Precision Medicines reported a third-quarter 2026 net loss of $94.2 million, up from $73.9 million a year earlier, while its loss per share narrowed to $3.23 from $3.36 on a larger share count. The company had $1.3 billion in cash and investments at September 30, 2026, which it says funds operations into 2028, and it has two FDA applications under review with target action dates of December 27, 2026 and January 29, 2027.

Key points

  • Net loss was $94.2 million for Q3 2026 versus $73.9 million for Q3 2025; loss per share was $3.23 versus $3.36.
  • General and administrative expenses rose to $42.7 million from $12.6 million, mainly on $17.2 million in higher personnel costs and $9.4 million in higher professional expenses.
  • Cash, cash equivalents and marketable securities were $1.3 billion at September 30, 2026, which the company says funds operations into 2028.
  • FDA target action dates are December 27, 2026 for relutrigine and January 29, 2027 for ulixacaltamide; Investor Day is November 12, 2026.

The filing

CompanyPraxis Precision Medicines, Inc. (PRAX)
Form8-K, current report
Filed with the SECNov 9, 2026, 7:02 AM ET
Accession number0001689548-26-000086

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:10 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.